Paolo Molinari’s Post

𝐇𝐞𝐚𝐥𝐭𝐡 𝐄𝐜𝐨𝐧𝐨𝐦𝐢𝐜𝐬 & 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 (𝐇𝐄𝐎𝐑) 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐. 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝐇𝐞𝐚𝐥𝐭𝐡 𝐄𝐜𝐨𝐧𝐨𝐦𝐢𝐜𝐬 & 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 (𝐇𝐄𝐎𝐑) 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/d5QFyDfV #Health Economics and Outcomes Research (HEOR) serves as a critical tool in comprehending the prescription patterns of healthcare providers and assessing real-world drug performance for actual patients, ultimately enhancing patient care. In the context of evolving healthcare landscapes characterized by precision medicine and value-based care, #HEOR is transitioning from a supporting function to a central role within pharmaceutical companies. It plays a pivotal role across the entire product life cycle, informing decisions in research and development, pricing, market access, strategic planning, and lifecycle management. The services encompassed by HEOR, utilized by both healthcare and #pharmaceutical entities, involve evaluating the value, cost, and cost-effectiveness of products or processes. HEOR functions as a valuable resource for healthcare decision-makers, including physicians, governments, payers, health ministries, and patients, aiding them in making informed comparisons and selecting optimal treatment options. *𝗕𝘆 𝗧𝘆𝗽𝗲: Consultancy, Contract Research Organizations *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Healthcare Providers, Healthcare Payers, Biotech/Pharma Companies, Government Organizations, Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻𝘀: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Axtria - Ingenious Insights, Avalon Health Economics LLC, Cardinal Health, ICON plc, IQVIA, McKesson, Medlior Health Outcomes Research Ltd., Optum, PharmaLex, Pharmaceutical Product Development, LLC (PPD), RTI Health Solutions, Syneos Health, PAREXEL International (India) Private Ltd, TCD #HEOR #HealthEconomics #OutcomesResearch #PrecisionMedicine #ValueBasedCare #Pharmaceuticals #PatientCare #ResearchAndDevelopment #MarketAccess #StrategicPlanning #LifecycleManagement #HealthcareDecisionMaking #CostEffectiveness #TreatmentOptions #RealWorldEvidence #HealthcareInnovation #HealthcareAnalytics #EvidenceBasedMedicine

Meeting Pharma's Needs Through Digital Health Suppliers 🤝 Pharma companies are increasingly digitizing post-COVID, highlighting the critical need for partnerships with digital health companies. When digital health suppliers evolve into strategic partners contribute to personalized, impactful healthcare solutions, driving better patient outcomes and advancing healthcare's patient-centered evolution. However, these partnerships demand more than just digital solutions, they require: 1️⃣ Demonstrating Value: Suppliers must showcase how their solutions add measurable value, such as improving patient outcomes or generating real-world evidence. 2️⃣ Collaboration Models: Pharma seeks collaboration without product ownership, especially in regulated spaces. 3️⃣ Quality, Security, and Privacy: Suppliers must align with industry standards to meet regulatory requirements and protect patient data. 4️⃣ Understanding Regulations: Competent suppliers need deep knowledge of industry regulations to navigate market access and commercialization challenges. 5️⃣ Flexibility for Localization: Suppliers must offer scalable solutions adaptable to diverse country requirements. 6️⃣ Understanding Patients and Providers: Top-tier suppliers tailor solutions to user needs, fostering positive behavior change. 7️⃣ Access to User Communities: Suppliers should provide access to user communities for better product refinement and adoption rates. 8️⃣ Identifying Relevant Solutions: Suppliers must suggest solutions aligned with pharma companies' healthcare needs, even when not explicitly defined. What do you think?💬 #Pharma #DigitalHealth #StrategicParterships

🌍 Market Access: The Key to Overcoming Future Challenges and Unleashing Success The development and launch of new drugs face increasing challenges in a highly competitive and regulated market. The average cost of bringing a product to market exceeds $2 billion, yet over 36% of launches in the U.S. fail to meet payer expectations. The key to success lies in a strong and well-executed market access strategy, addressing aspects such as clinical evidence, stakeholder negotiation, and ensuring affordable supplies. 🎯 Key Elements for a Successful Market Access Strategy: -  Winning Ambition: Define clear goals aligned with business objectives. Establish access timelines, volumes, discounts, and reimbursements. -  Where to Play: Consider treatment context, prioritize stakeholders, evaluate access options and their trade-offs. -  How to Win: Communicate brand value, determine pricing, contracting, reimbursement, affordability, and compliance. -  Execution: Prioritize cross-functional actions, monitor outcomes, and adapt to the market. Requires flexible resource allocation, best practice application, strategic adjustments, and concessions for sustainable and profitable access. 📊 Principles for an Effective Market Access Strategy: • Rigor and Discipline in Strategy Development: Ensure adequate resources and cross-functional execution in market access, branding, healthcare, HEOR, sales, and finance. • Incorporate market access perspective early in clinical development to demonstrate and communicate value to stakeholders throughout the product lifecycle. • Develop a tailored value and evidence strategy to meet the unmet needs of each stakeholder and treatment type. • Flexibility to adapt to changes (customer, competition, political, economic, social, and technological) and ensure sustainable and profitable access. 🌟 In a complex business environment, a solid market access strategy is essential for the success of pharmaceutical product launches. Embracing disciplined and cross-functional approaches ensures effective and sustainable execution in a competitive and ever-changing market. #MarketAccess #GlobalMarket #BusinessStrategy #MarketPenetration #HealthcareAccess #MarketDevelopment #MarketOpportunities #MarketResearch #MarketTrends #MarketAnalysis

𝗥𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗯𝗲 𝗪𝗼𝗿𝘁𝗵 $𝟲.𝟯𝟳 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟭 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲: https://lnkd.in/eMeerwE3 The global Real-World Evidence (RWE) solutions market, valued at $2.62 billion in 2023, is projected to grow to $6.37 billion by 2031, with an estimated value of $2.94 billion in 2024, reflecting a CAGR of 11.7% from 2024 to 2031. This growth is driven by the increasing prevalence of chronic illnesses, delays in drug development, rising development costs, and the push towards personalized and value-based healthcare. The expanding use of RWE in drug development and commercialization, along with emerging economies and the emphasis on comprehensive RWE services, further fuel market expansion. Organizations are adopting end-to-end strategies that leverage data and evidence to enhance R&D and commercialization through insight-driven decision-making, aiming to improve population health and achieve better outcomes. 𝗥𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: *𝗕𝘆 𝗖𝗼𝗺𝗽𝗼𝗻𝗲𝗻𝘁: Datasets, Consulting Services *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Market Access & Reimbursement/Coverage Decisions, Drug Development & Approvals, Post Market Surveillance, Medical Device Development & Approvals, Other Applications *𝗕𝘆 𝗘𝗻𝗱 𝗨𝘀𝗲𝗿: Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, Other End Users *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻𝘀: North America (U.S. and Canada), Europe (Germany, U.K., France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Latin America and the Middle East & Africa *𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: IQVIA, Elevance Health, ICON plc, Clinigen, Cognizant Technology Solutions, Revvity, Thermo Fisher Scientific, Oracle, SAS, HealthVerity #RealWorldEvidence #RWE #HealthcareData #EvidenceBasedMedicine #HealthOutcomes #DataDrivenHealthcare #PersonalizedMedicine #ValueBasedCare #ChronicIllness #DrugDevelopment #ClinicalResearch #HealthAnalytics #MedicalResearch #HealthInnovation #DataScience #PharmaInsights #RWEInsights #HealthcareTrends #EndToEndRWE #HealthTech

Are you currently working in an agency setting and contemplating a career shift into the pharmaceutical industry? If so, this promises to be a helpful webinar. Having made this switch myself, I can personally attest to the value agency experience brings to the #pharma sector. I’m eager to hear if others share similar experiences and to discuss how this pivotal career move can be made successfully. #medcomms #careerchange

🔬📈 Substantial Growth Ahead for the Clinical Trials Market! 📈🔬 The #Clinical #Trials Market, valued at USD 51.67 billion in 2023, is projected to #reach nearly USD 78.36 billion by 2030, growing at a CAGR of 6.13% from 2024 to 2030. Market Overview: Clinical trials are essential research processes that evaluate new tests and treatments and their effects on human #health outcomes. This market encompasses all testing procedures conducted on a product before it gains market approval. The demand for clinical trials is propelled by the ongoing pursuit of innovative therapies and #treatments. Get details analysis: https://cutt.ly/setqgRUu Key Market Drivers: Innovative Therapies and Treatments: Continuous development of new medical treatments drives the need for clinical trials. Global Expansion: Increasing globalization of clinical trials to diverse #patient populations and regions. Technological Advancements: Use of advanced technologies for efficient trial design and data analysis. Leading Players: IQVIA PPD PAREXEL International (India) Private Ltd Medpace Holdings, Inc. The Clinical Trials Market is set for substantial growth, supported by the ongoing efforts of leading players to bring new and effective therapies to market. #ClinicalTrials #MarketGrowth #HealthcareResearch #InnovativeTherapies #MedicalResearch #GlobalHealth

𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 𝐭𝐨 𝐖𝐚𝐭𝐜𝐡 𝐢𝐧 𝟐𝟎𝟐𝟒 𝐚𝐧𝐝 𝐁𝐞𝐲𝐨𝐧𝐝 📈🩺 𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐆𝐮𝐢𝐝𝐞: https://lnkd.in/dk_pTq_B Healthcare market trends are constantly evolving as advancements in technology, changes in regulatory policies, and shifts in consumer behavior continue to shape the industry. One major trend that has been on the rise is the increased adoption of telemedicine and virtual care services, particularly in response to the COVID-19 pandemic. These services have allowed patients to receive medical care remotely, reducing exposure risks and increasing accessibility. Additionally, personalized medicine and precision healthcare have gained traction as healthcare providers seek more tailored treatment options based on individual genetic makeups and lifestyle factors. The rising costs of healthcare have also fueled a growing demand for value-based care models focused on improving patient outcomes while containing expenses. Overall, staying current with these trends is crucial for healthcare professionals to effectively navigate the rapidly changing landscape of the industry. 𝑨𝒄𝒄𝒐𝒓𝒅𝒊𝒏𝒈 𝑻𝒐 𝑺𝑵𝑺 𝑰𝒏𝒔𝒊𝒅𝒆𝒓,𝑻𝒉𝒆 𝑯𝒆𝒂𝒍𝒕𝒉𝒄𝒂𝒓𝒆 𝑴𝒂𝒓𝒌𝒆𝒕 𝒔𝒊𝒛𝒆 𝒘𝒂𝒔 𝒆𝒔𝒕𝒊𝒎𝒂𝒕𝒆𝒅 𝑼𝑺𝑫 21222.52 𝒃𝒊𝒍𝒍𝒊𝒐𝒏 𝒊𝒏 2023 𝒂𝒏𝒅 𝒊𝒔 𝒆𝒙𝒑𝒆𝒄𝒕𝒆𝒅 𝒕𝒐 𝒓𝒆𝒂𝒄𝒉 𝑼𝑺𝑫 41670.45 𝒃𝒊𝒍𝒍𝒊𝒐𝒏 𝒃𝒚 2031 𝒂𝒕 𝒂 𝑪𝑨𝑮𝑹 𝒐𝒇 8.8% 𝒅𝒖𝒓𝒊𝒏𝒈 𝒕𝒉𝒆 𝒇𝒐𝒓𝒆𝒄𝒂𝒔𝒕 𝒑𝒆𝒓𝒊𝒐𝒅 𝒐𝒇 2024-2031. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐩𝐫𝐨𝐟𝐢𝐥𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐬𝐭𝐮𝐝𝐲 𝐚𝐫𝐞 Pfizer, Novartis, Merck Group, Roche, GSK, Sanofi, Johnson & Johnson, AstraZeneca, AbbVie, UnitedHealth Group, Medtronic, GE HealthCare, McKesson, Abbott, Johnson & Johnson, Philips, Pfizer, CVS Health Siemens Healthineers, Fresenius Medical Care, BD, GE HealthCare, Stryker, Cardinal Health, Eli Lilly and Company, Novo Nordisk, Roche, AstraZeneca, Amgen, Walgreens Boots Alliance Thermo Fisher Scientific, IDEXX , SGS, Quest Diagnostics, Revvity, Exact Sciences, bioMérieux, Sonic Healthcare, Bayer (To view Full list of companies, Ask for Sample Guide) #HealthcareMarket #HealthcareIndustry #HealthTech #MedicalMarket #HealthcareInnovation #HealthcareBusiness #HealthcareTrends #HealthcareEconomics #HealthcareInvestments #MedicalTechnology #HealthcareSolutions #HealthEconomics #HealthcareGrowth #HealthcareMarketing #DigitalHealth #HealthCare #HealthServices #GlobalHealthcare #HealthcareFinance #HealthcareManagement #Pharmaceuticals

Overdependence on sales data for commercial and patient insights is limiting opportunities for pharma brand teams to improve both patient outcomes and commercial performance. 🟢 Learn how a patient-centric analytics platform is key to uplifting care and capturing full market potential. 👉 https://lnkd.in/ghqGnfKb #PCI #PatientCentricIntelligence #ProspectionAI

🌟 IQVIA : Unifying data. Empowering life sciences. 🚀IQVIA, formerly known as QUINTILES RESEARCH (INDIA) PRIVATE LIMITED and IMS Health before their merger🤝 in 2016, has achieved significant success in the healthcare and pharmaceutical services . Here are several key factors that have contributed to IQVIA's success: 🌐 Comprehensive Service Offerings: IQVIA offers a wide range of services spanning clinical research, data analytics, consulting, technology solutions, and commercialization services. 📊 Data and Analytics Capabilities: One of IQVIA's key strengths is its data and analytics capabilities. The company leverages vast amounts of healthcare data from various sources to provide insights that inform decision-making for clients. This includes real-world evidence, patient data, prescription data, and market intelligence. 🌍 Global Reach and Scale: This global footprint allows them to serve multinational clients and navigate diverse regulatory environments effectively. 💡 Focus on Innovation and Technology: IQVIA invests heavily in innovation and technology to drive efficiencies and improve outcomes for clients. This includes advancements in data analytics, AI-driven insights, digital technologies for clinical trials, and patient engagement solutions. 🤝 Strategic Acquisitions and Partnerships: The merger of QUINTILES RESEARCH (INDIA) PRIVATE LIMITED and IMS Health brought together complementary strengths in clinical research and data analytics. 🤝 Client-Centric Approach: IQVIA is known for its focus on understanding and addressing client needs. By building strong relationships and delivering tailored solutions, IQVIA has earned the trust of leading pharmaceutical companies and healthcare organizations. #IQVIAData #HealthcareDataLeader #UnifiedHealthcare #DataIntegration #IQVIACORE #LifeSciencesSolutions #ClinicalTrialOptimization #IQVIACompliance #EffectiveMarketing #DrugDevelopment #IQVIAInnovation

Article just out today in the Financial Times! "IQVIA Named a Leader in Medical Affairs and Regulatory Operations by Everest Group." Delivering health innovations to patients requires many different specialized skills and coordinated teamwork. We are delighted to be part of such a strong global life sciences network with offices around the globe! "...leading, independent research firm, Everest Group, has recognized IQVIA as a Leader in its Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024 survey, which measures both market impact and delivery effectiveness. The Everest Group report highlights IQVIA’s focus on innovation and its comprehensive portfolio of solutions that accelerates drug development from molecule to market. IQVIA partners with customers to plan, generate and disseminate trustworthy clinical and medical evidence which drives the right stakeholder dialogue throughout the asset lifecycle to advance regulatory and healthcare decision making that improves patient outcomes." #healthinnovation #financialtimes https://lnkd.in/dJ3K3NFr